Adjuvant immunotherapy with nonviable Mycobacterium smegmatis in resected primary lung carcinoma. A randomized clinical trial of 219 patients

MLA

G, Decroix, et al. “Adjuvant Immunotherapy with Nonviable Mycobacterium Smegmatis in Resected Primary Lung Carcinoma. A Randomized Clinical Trial of 219 Patients.” Cancer, vol. 53, no. 4, Feb. 1984. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........cdcc5a0fcdcaf2c28cb46610d8b49f90&authtype=sso&custid=ns315887.

APA

G, D., C, C., D, F., B, A., B, L., V, M., T, L., P, B., C, F., & J L, R. (1984). Adjuvant immunotherapy with nonviable Mycobacterium smegmatis in resected primary lung carcinoma. A randomized clinical trial of 219 patients. Cancer, 53(4).

Chicago

G, Decroix, Chastang C, Fichet D, Asselain B, Lebeau B, Morice V, Lepage T, Babo P, Fabre C, and Rebischung J L. 1984. “Adjuvant Immunotherapy with Nonviable Mycobacterium Smegmatis in Resected Primary Lung Carcinoma. A Randomized Clinical Trial of 219 Patients.” Cancer 53 (4). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........cdcc5a0fcdcaf2c28cb46610d8b49f90&authtype=sso&custid=ns315887.